Evidence map›Paper›PMID 37942327›Full record

ArticleFrontiers in immunology2023

CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling.

Sean P Giblin, Sashini Ranawana, Shyreen Hassibi, Holly L Birchenough, Kyle T Mincham, Robert J Snelgrove, Tomoko Tsuchiya, Shiro Kanegasaki, Douglas Dyer, James E Pease

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. The N-terminal ELRThe Journal of biological chemistry · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sean P GiblinNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Sashini RanawanaNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Shyreen HassibiNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Holly L BirchenoughWellcome Centre for Cell-Matrix Research, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
Kyle T MinchamNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Robert J SnelgroveNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Tomoko TsuchiyaResearch Institute, National Center for Global Health and Medicine, Shinjuku-ku, Japan.
Shiro KanegasakiHeavy Ion Medical Center, Gunma University, Maebashi, Japan.
Douglas DyerWellcome Centre for Cell-Matrix Research, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
James E PeaseNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Imperial College London · GBGunma University Hospital · JPManchester Academic Health Science Centre · GBNational Center for Global Health and Medicine · JPUniversity of Manchester · GB

Funding

Wellcome TrustWellcome Trust 203128/A/16/ZWellcome Trust 209458/Z/17/ZWellcome Trust 215539Wellcome Trust 218570/Z/19/Z
6 · The paper itself

Abstract

Introduction: CXCL17 is a mucosally secreted protein, and the most recently identified human chemokine, an assignment based on protein fold prediction and chemotactic activity for leukocytes. However, these credentials have been the subject of much recent discussion and no experimental evidence has been presented regarding the definitive structure of CXCL17. In this study, we evaluated the structural and chemoattractant credentials of CXCL17 to better characterize this molecule, and gain deeper insights into its functional role as a glycosaminoglycan (GAG) binding protein. Methods: In the absence of structural information, Results: All modeling efforts failed to support classification of CXCL17 as a chemokine based on its predicted conformation. Recombinant CXCL17 was observed to dimerize as a function of concentration, a characteristic of several chemokines. Contrary to a previous report, CXCL17 was not chemotactic for murine splenocytes, although it was a low-potency chemoattractant for human neutrophils at micromolar concentrations, several orders of magnitude higher than those required for CXCL8. As anticipated owing to its highly basic nature, CXCL17 bound to GAGs robustly, with key C-terminal motifs implicated in this process. While inactive via CXCR1, CXCL17 was found to inhibit CXCR1-mediated chemotaxis of transfectants to CXCL8 in a dose-dependent manner. Discussion: In summary, despite finding little evidence for chemokine-like structure and function, CXCL17 readily bound GAGs, and could modulate chemotactic responses to another chemokine

Indexed as

ChemokinesGlycosaminoglycansAnimalsChemokines, CXCChemotaxisHumansMammalsMiceNeutrophilsChemokinesChemokines, CXCCXCL17 protein, humanCXCL17 protein, mouseGlycosaminoglycanschemokinechemotaxisCXCL8CXCR1glycosaminoglycan (GAG)modelmucosalneutrophil

Identifiers

PMID37942327
PMCPMC10628517
OpenAlexW4387939319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.